We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Spectroscopy Aids Breast Cancer Diagnosis

By LabMedica International staff writers
Posted on 09 Jan 2013
Diffuse reflectance spectroscopy collects and analyzes light after it has interacted with the sample and this gives a unique spectrographic signature.

This special type of spectroscopy has been used locate calcium deposits during a biopsy and could greatly improve the accuracy of diagnosing breast cancer. More...


A team from Massachusetts Institute of Technology (Cambridge, MA, USA) and Case Western Reserve University (Cleveland, OH, USA) have investigated whether diffuse reflectance spectroscopy can help to diagnose breast cancer. They examined 203 tissue samples within minutes of their removal from 23 patients. Each sample could be one of three types, each with its own spectrographic signature. It could be healthy, it could contain lesions with no microcalcifications, or it could contain lesions with microcalcifications.

Diffuse reflectance and Raman spectroscopic measurements were performed using a portable, compact clinical system. This instrument contains a xenon flash lamp (370–740 nm) to obtain diffuse reflectance spectra, and a diode laser (830 nm) for Raman excitation. For spectral acquisition, the probe was gently brought into contact with the tissue specimen and the spectra were collected with room lights off. Spectra were recorded from multiple tissue sites of interest from each tissue core as well as from several cores in each biopsy, and thus the number of collected spectra varied from patient to patient. By analyzing these patterns, the team produced a computer algorithm that showed a success rate of 97% in identifying tissue with microcalcifications.

Normally a radiologist takes X-rays from three different angles to locate the tiny calcium deposits, then inserts a needle into the tissue and removes up to 10 tissue samples. A pathologist then tests these samples to see if they contain microcalcifications, but in 15% to 25% of cases, it is not easy to locate and take a tissue sample accurately, resulting in an inconclusive diagnosis. This means the patient has to have more X-rays and undergo more invasive surgery to retrieve further samples.

Maryann Fitzmaurice, MD, PhD, cosenior author, said, "Microcalcifications are most often seen in breast tumors, but they can also occur, albeit rarely, in other types of cancer. If they don't get them on the first pass, they usually don't get them at all. It can become a very long and arduous procedure for the patient, with a lot of extra X-ray exposure, and in the end they still don't get what they're after, in one out of five patients.

James Tunnell, PhD, an associate professor at the University of Texas (Austin, TX, USA), who not involved in the study describes the study as a "good first step" toward a system that could have a big impact on breast cancer diagnosis. "This technology can be integrated into the system that is already used to take biopsies. It's a very simple technology that can get the same amount of accuracy as more complicated systems." The study was published online on December 24, 2012, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:
Massachusetts Institute of Technology
Case Western Reserve University
University of Texas



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.